Header Logo

Connection

SANKAR NAVANEETHAN to Cardiovascular Diseases

Back to Details
This is a "connection" page, showing publications SANKAR NAVANEETHAN has written about Cardiovascular Diseases.
SANKAR NAVANEETHAN
Connection Strength
4.670
Cardiovascular Diseases
  1. Emerging strategies to reduce kidney function decline and improve cardiovascular outcomes. Curr Opin Nephrol Hypertens. 2023 09 01; 32(5):401-403.
    View in: PubMed
    Score: 0.352
  2. Echocardiographic parameters and cardiovascular disease in Japanese- and US-based CKD cohorts. Kidney Int. 2023 05; 103(5):837-839.
    View in: PubMed
    Score: 0.343
  3. Prevalence, correlates and outcomes of absolute and functional iron deficiency anemia in nondialysis-dependent chronic kidney disease. Nephrol Dial Transplant. 2021 01 01; 36(1):129-136.
    View in: PubMed
    Score: 0.292
  4. Association between intensity of statin therapy and mortality in persons with chronic kidney disease. Nephrol Dial Transplant. 2020 02 01; 35(2):312-319.
    View in: PubMed
    Score: 0.274
  5. Primary and Secondary Prevention of Cardiovascular Disease in Patients with Chronic Kidney Disease. Curr Atheroscler Rep. 2019 06 22; 21(9):32.
    View in: PubMed
    Score: 0.263
  6. Prevalence, Predictors, and Outcomes of Pulmonary Hypertension in CKD. J Am Soc Nephrol. 2016 Mar; 27(3):877-86.
    View in: PubMed
    Score: 0.203
  7. Elevated pulmonary pressure: A novel risk marker in kidney disease? Kidney Int. 2015 Jul; 88(1):7-9.
    View in: PubMed
    Score: 0.200
  8. Outcomes of infected cardiovascular implantable devices in dialysis patients. Am J Nephrol. 2014; 40(3):280-7.
    View in: PubMed
    Score: 0.190
  9. Albuminuria: when urine predicts kidney and cardiovascular disease. Cleve Clin J Med. 2014 Jan; 81(1):41-50.
    View in: PubMed
    Score: 0.180
  10. Role of statins in preventing adverse cardiovascular outcomes in patients with chronic kidney disease. Curr Opin Nephrol Hypertens. 2011 Mar; 20(2):146-52.
    View in: PubMed
    Score: 0.148
  11. HMG CoA reductase inhibitors (statins) for kidney transplant recipients. Cochrane Database Syst Rev. 2009 Apr 15; (2):CD005019.
    View in: PubMed
    Score: 0.130
  12. Associations of serum uric acid with cardiovascular events and mortality in moderate chronic kidney disease. Nephrol Dial Transplant. 2009 Apr; 24(4):1260-6.
    View in: PubMed
    Score: 0.126
  13. Antihypertensive agents in patients with diabetes: trade-off between renal and cardiovascular protection. Diabetes Educ. 2006 Jul-Aug; 32(4):596-602.
    View in: PubMed
    Score: 0.107
  14. Statins in patients with chronic kidney disease: evidence from systematic reviews and randomized clinical trials. PLoS Med. 2006 May; 3(5):e123.
    View in: PubMed
    Score: 0.106
  15. 2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association. Circulation. 2024 02 20; 149(8):e347-e913.
    View in: PubMed
    Score: 0.090
  16. Utilization Rates of SGLT2 Inhibitors Among Patients With Type 2 Diabetes, Heart Failure, and Atherosclerotic Cardiovascular Disease: Insights From the Department of Veterans Affairs. JACC Heart Fail. 2023 08; 11(8 Pt 1):933-942.
    View in: PubMed
    Score: 0.086
  17. Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association. Circulation. 2023 02 21; 147(8):e93-e621.
    View in: PubMed
    Score: 0.084
  18. A Mistake Not to Be Repeated: What Can We Learn from the Underutilization of Statin Therapy for Efficient Dissemination of Cardioprotective Glucose Lowering Agents? Curr Cardiol Rep. 2022 06; 24(6):689-698.
    View in: PubMed
    Score: 0.080
  19. Correlates of Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes Mellitus (from the Department of Veterans Affairs). Am J Cardiol. 2022 06 01; 172:7-10.
    View in: PubMed
    Score: 0.079
  20. Utilization Rates of SGLT2 Inhibitors and GLP-1 Receptor Agonists and Their Facility-Level Variation Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes: Insights From the Department of Veterans Affairs. Diabetes Care. 2022 02 01; 45(2):372-380.
    View in: PubMed
    Score: 0.079
  21. Correlates of SGLT-2-inhibitiors use among patients with atherosclerotic cardiovascular disease and type 2 diabetes mellitus: Insights from the department of veterans affairs. Am Heart J. 2022 06; 248:160-162.
    View in: PubMed
    Score: 0.078
  22. Social Determinants of Health and Comorbidities Among Individuals with Atherosclerotic Cardiovascular Disease: The Behavioral Risk Factor Surveillance System Survey. Popul Health Manag. 2022 02; 25(1):39-45.
    View in: PubMed
    Score: 0.075
  23. Chronic kidney disease, atherosclerotic plaque characteristics on carotid magnetic resonance imaging, and cardiovascular outcomes. BMC Nephrol. 2021 02 24; 22(1):69.
    View in: PubMed
    Score: 0.074
  24. Trends in the Causes of Death among Kidney Transplant Recipients in the United States (1996-2014). Am J Nephrol. 2018; 48(6):472-481.
    View in: PubMed
    Score: 0.063
  25. Cardiovascular Events after New-Onset Atrial Fibrillation in Adults with CKD: Results from the Chronic Renal Insufficiency Cohort (CRIC) Study. J Am Soc Nephrol. 2018 12; 29(12):2859-2869.
    View in: PubMed
    Score: 0.063
  26. High-density lipoprotein cholesterol and causes of death in chronic kidney disease. J Clin Lipidol. 2018 Jul - Aug; 12(4):1061-1071.e7.
    View in: PubMed
    Score: 0.060
  27. Predicting timing of clinical outcomes in patients?with chronic kidney disease and severely decreased glomerular filtration rate. Kidney Int. 2018 06; 93(6):1442-1451.
    View in: PubMed
    Score: 0.060
  28. Blood pressure parameters and morbid and mortal outcomes in nondialysis-dependent chronic kidney disease. Curr Opin Nephrol Hypertens. 2018 01; 27(1):16-22.
    View in: PubMed
    Score: 0.059
  29. Cardiovascular impact in patients undergoing maintenance hemodialysis: Clinical management considerations. Int J Cardiol. 2017 Apr 01; 232:12-23.
    View in: PubMed
    Score: 0.055
  30. A Whole-Grain Diet Reduces Cardiovascular Risk Factors in Overweight and Obese Adults: A Randomized Controlled Trial. J Nutr. 2016 Nov; 146(11):2244-2251.
    View in: PubMed
    Score: 0.055
  31. Interventions for lowering plasma homocysteine levels in dialysis patients. Cochrane Database Syst Rev. 2016 May 31; (5):CD004683.
    View in: PubMed
    Score: 0.053
  32. Interventions for lowering plasma homocysteine levels in kidney transplant recipients. Cochrane Database Syst Rev. 2015 May 04; (5):CD007910.
    View in: PubMed
    Score: 0.049
  33. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev. 2014 May 31; (5):CD007784.
    View in: PubMed
    Score: 0.046
  34. HMG CoA reductase inhibitors (statins) for kidney transplant recipients. Cochrane Database Syst Rev. 2014 Jan 28; (1):CD005019.
    View in: PubMed
    Score: 0.045
  35. Exercise-induced lowering of chemerin is associated with reduced cardiometabolic risk and glucose-stimulated insulin secretion in older adults. J Nutr Health Aging. 2014; 18(6):608-15.
    View in: PubMed
    Score: 0.045
  36. HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database Syst Rev. 2013 Sep 11; (9):CD004289.
    View in: PubMed
    Score: 0.044
  37. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012 Aug 21; 157(4):263-75.
    View in: PubMed
    Score: 0.041
  38. The effect of folic acid based homocysteine lowering on cardiovascular events in people with kidney disease: systematic review and meta-analysis. BMJ. 2012 Jun 13; 344:e3533.
    View in: PubMed
    Score: 0.040
  39. Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials. Nephrol Dial Transplant. 2011 Sep; 26(9):2827-47.
    View in: PubMed
    Score: 0.037
  40. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med. 2010 Jul 06; 153(1):23-33.
    View in: PubMed
    Score: 0.035
  41. HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database Syst Rev. 2009 Jul 08; (3):CD004289.
    View in: PubMed
    Score: 0.033
  42. HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database Syst Rev. 2009 Apr 15; (2):CD004289.
    View in: PubMed
    Score: 0.032
  43. Haemoglobin targets: we were wrong, time to move on. Lancet. 2007 Feb 03; 369(9559):346-50.
    View in: PubMed
    Score: 0.028
  44. Prevalence of the Cardiovascular-Kidney-Metabolic Syndrome in the United States. J Am Coll Cardiol. 2024 May 07; 83(18):1824-1826.
    View in: PubMed
    Score: 0.023
  45. Association of Blood Pressure Variability and Diuretics With Cardiovascular Events in Patients With Chronic Kidney Disease Stages 1-5. Hypertension. 2021 03 03; 77(3):948-959.
    View in: PubMed
    Score: 0.018
  46. Safety analysis of primary bariatric surgery in patients on chronic dialysis. Surg Endosc. 2016 06; 30(6):2583-91.
    View in: PubMed
    Score: 0.013
  47. Chronic Renal Insufficiency Cohort Study (CRIC): Overview and Summary of Selected Findings. Clin J Am Soc Nephrol. 2015 Nov 06; 10(11):2073-83.
    View in: PubMed
    Score: 0.013
  48. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care. 2014 Oct; 37(10):2864-83.
    View in: PubMed
    Score: 0.012
  49. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ. 2008 Mar 22; 336(7645):645-51.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.